.
PRIVATE • DISCREET • OFFICE-BASED CARE
Brixadi Injections for Opioid Use Disorder
Long-Acting Buprenorphine Treatment — Without the Daily Routine
Monthly treatment personally guided by Dr. Watson.
Effective, affordable treatment shouldn’t have to put your life on hold.
Brixadi Treatment with Dr. Watson
A long-acting option. A treatment plan built around you.
Brixadi is an extended-release form of buprenorphine available in both weekly and monthly injections for opioid use disorder.
Through Dr. Watson’s Direct Physician Care model, treatment is personally guided and individualized. Dr. Watson works directly with each patient to determine whether Brixadi, Sublocade, or oral buprenorphine best fits their treatment needs, lifestyle, and goals.
For many established patients, the biggest change isn’t simply how often they take medication. It’s getting the daily treatment routine out of their lives.
FREEDOM FROM THE DAILY ROUTINE.
SINCE 2018
International use as Buvidal
Brixadi Has a Longer History Than You May Think
Although Brixadi is relatively new in the United States, the medication is not new internationally.
The same extended-release buprenorphine technology has been used as Buvidal in Europe and other countries since 2018, providing years of real-world experience with weekly and monthly injectable buprenorphine before Brixadi became available in the U.S.
For patients considering a long-acting option, Brixadi adds something important: another way to individualize treatment beyond taking buprenorphine every day.
WEEKLY + MONTHLY
Extended-release options
Key Features of BRIXADI
FREEDOM — From the Daily Routine
No medication to remember every morning. For many established patients, treatment begins to move into the background of everyday life.
Weekly or Monthly Flexibility
Brixadi treatment offers both weekly and monthly dosing, giving Dr. Watson additional flexibility to individualize treatment as a patient’s needs change.
More Injection-Site Options
Brixadi can be administered subcutaneously in several approved locations, providing more flexibility than an abdomen-only injection.
A Smaller-Volume Injection
Brixadi uses a relatively small injection volume and a thin needle. For some patients, that can make the injection experience different from other long-acting buprenorphine options.
IMPORTANT BRIXADI DOSING NOTE
For patients new to buprenorphine treatment, Brixadi has specific dosing and injection-site instructions that may differ depending on whether weekly or monthly treatment is being used.
Dr. Watson reviews the appropriate dose, timing, and injection site individually with each patient.
Who Can Use Brixadi?
Brixadi is FDA-approved for the treatment of moderate to severe opioid use disorder in people who have started treatment with a dose of transmucosal buprenorphine or who are already being treated with buprenorphine.
For established patients, the more practical question is whether Brixadi fits the way you want to live and manage your treatment.
Dr. Watson considers your current buprenorphine treatment, stability, goals, lifestyle, and preference for weekly or monthly dosing when deciding whether Brixadi is an appropriate option.
Treatment is individualized. Brixadi may be the right choice for some patients, while Sublocade or oral buprenorphine may be a better fit for others.
The BRIXADI Advantage
- Comfort: A smaller needle ensures a less painful administration experience.
- Discreet: The lesser volume means minimal and less noticeable posttreatment nodules.
- Customizable: The flexibility of multiple injection sites empowers patients, offering choices tailored to their comfort.
Brixadi or Sublocade — Which Is Right for Me?
Both Brixadi treatment and Sublocade are long-acting forms of buprenorphine used to treat opioid use disorder, but they are not identical.
Brixadi offers both weekly and monthly dosing and several injection-site options. Sublocade is given monthly and has a different formulation, dosing approach, and injection experience.
There isn’t one injection that’s best for everyone.
Dr. Watson works with each patient individually to decide whether Brixadi, Sublocade, or oral buprenorphine makes the most sense for their treatment and lifestyle.
The goal is to find the treatment that gives you stability — and allows treatment to take up less space in your life.
Direct Physician Care with Dr. Watson gives you access to a precise and focused route to recovery. This streamlined approach eliminates distractions, providing the best opportunity for a successful and enduring recovery.
References
- BRIXADI. Prescribing information. Braeburn Inc; 2023.
- Lofwall MR, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764-773. [Link to Study]